Clinical Trials Logo

Coronary Artery Stenosis clinical trials

View clinical trials related to Coronary Artery Stenosis.

Filter by:

NCT ID: NCT01182428 Completed - Clinical trials for Coronary Artery Disease

XIENCE V: SPIRIT WOMEN Sub-study

Start date: September 2008
Phase: Phase 4
Study type: Interventional

The purpose of this Clinical Evaluation is the continued assessment of the XIENCE Everolimus Eluting Coronary Stent System (XIENCE V® and XIENCE PRIMEā„¢ EECSS) with the primary focus on clinical outcomes in the treatment of female patients with de novo coronary artery lesions, and the characterization of the female population undergoing stent implantation with a XIENCE stent.

NCT ID: NCT01178268 Completed - Clinical trials for Coronary Artery Disease

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)

Start date: August 2010
Phase: Phase 4
Study type: Interventional

This is a prospective, randomized, active-controlled, open label, parallel two-arm, multi-center, post-approval study descriptively comparing the XIENCE V EECSS to the CYPHER SELECT PLUS Sirolimus-Eluting Coronary Stent System (SECSS) ("CYPHER SELECT PLUS") during commercial use in China.

NCT ID: NCT01137786 Completed - Clinical trials for Coronary Artery Stenosis

Kidney Damage in Patients With Normal eGFR

Start date: December 2010
Phase: Phase 4
Study type: Interventional

This is a pilot study, randomized, double-blind, parallel group comparison of two iodinated contrast agents used during percutaneous coronary intervention (PCI). All patients enrolled must have normal eGFR. Statistical summaries will be presented to analyse the various laboratory tests for the two groups.

NCT ID: NCT01136876 Completed - Clinical trials for Coronary Artery Stenosis

Kidney Damage in Patients With Moderate Fall in eGFR

Start date: November 2010
Phase: Phase 4
Study type: Interventional

To compare Iopamidol injection 370 and Iodixanol 320 in evaluating Neutrophil Gelatinase-Associated Lipocalin (NGAL) in patients with moderate fall in eGFR

NCT ID: NCT01120379 Completed - Clinical trials for Coronary Artery Disease

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)

XVU-LTF
Start date: July 2008
Phase: N/A
Study type: Observational

XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. The objectives of this study are - To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and - To support the Food and Drug Administration (FDA) dual antiplatelet therapy (DAPT) initiative. This initiative is designed to evaluate the composite of all death, myocardial infarction (MI) and stroke (MACCE) and the survival of patients that are free from Academic Research Consortium (ARC) definite or probable stent thrombosis (ST) and that have been treated with drug eluting stents (DES) and extended dual antiplatelet therapy.

NCT ID: NCT01115933 Completed - Clinical trials for Coronary Artery Disease

A Clinical Evaluation of the XIENCE PRIME Small Vessel Everolimus Eluting Coronary Stent System in Japanese Population

SV JAPAN
Start date: April 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of the AVJ-09-385 Small Vessel Everolimus Eluting Coronary Stent System (EECSS) (2.25 mm diameter stent) in treatment of subjects with ischemic heart disease caused by de novo lesions.

NCT ID: NCT01106534 Completed - Clinical trials for Coronary Artery Disease

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort

XVU-AV DAPT
Start date: August 2009
Phase: Phase 4
Study type: Interventional

XIENCE V USA is a prospective, multi-center, multi-cohort postapproval study. The objectives of this study are - To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and - To support the Food and Drug Administration (FDA) dual antiplatelet therapy (DAPT) initiative. This initiative is designed to evaluate the composite of all death, myocardial infarction (MI) and stroke (MACCE) and the survival of patients that are free from Academic Research Consortium (ARC) definite or probable stent thrombosis (ST) and that have been treated with drug eluting stents (DES) and extended dual antiplatelet therapy.

NCT ID: NCT01086228 Completed - Clinical trials for Coronary Artery Disease

XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan

Start date: March 2010
Phase: N/A
Study type: Observational

The objectives of this post-marketing surveillance, conducted in Japan, is to know the frequency, type and degree of device malfunction, to assure the safety of the medical device, and to collect information on evaluation of the efficacy and safety.

NCT ID: NCT01023789 Completed - Clinical trials for Coronary Artery Disease

ABSORB EXTEND Clinical Investigation

ABSORB EXTEND
Start date: January 2010
Phase: N/A
Study type: Interventional

The ABSORB EXTEND trial is to continue the assessment of the safety and performance of the ABSORB Bioresorbable Vascular Scaffold (BVS) System ABSORB BVS is currently in development at Abbott Vascular.

NCT ID: NCT00967876 Completed - Clinical trials for Coronary Artery Stenosis

Coronary Artery Stent Evaluation With 320-slice Computed Tomography - The CArS 320 Study

CARS-320
Start date: April 2009
Phase: N/A
Study type: Observational

The investigators aim at analyzing the diagnostic accuracy of 320-row CT for coronary stents.